gastroesophageal adenocarcinoma

Jazz and Zymeworks’ Ziihera Achieves Practice-Changing Results in Phase 3 Trial for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

1 week ago talkbio0Tagged erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, Zanidatamab, Ziihera, Zymeworks

Ziihera; zanidatamab; Jazz Pharmaceuticals; Zymeworks; HER2; gastroesophageal adenocarcinoma; HERIZON-GEA-01; stomach cancer

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

2 months ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

Friday Five: ESMO Looms Large, Arcus’ TIGIT Revival, and J&J’s Myeloma Advances

3 months ago talkbio0Tagged 2025, Arcus Biosciences, domvanalimab, ESMO, gastroesophageal adenocarcinoma, immuno-oncology, J&J, Multiple Myeloma, oncology clinical trials, Substance with programmed cell death protein 1 inhibitor mechanism of action (substance), TIGIT antibody, zimberelimab

ESMO 2025; Arcus Biosciences; domvanalimab; TIGIT antibody; gastroesophageal adenocarcinoma; J&J; multiple myeloma; immuno-oncology; PD-1 inhibitor; zimberelimab; oncology clinical trials